


## Auristatin F

<b>Cat. No.:</b>	HY-15583
<b>CAS No.:</b>	163768-50-1
<b>Molecular Formula:</b>	C <sub>40</sub> H <sub>67</sub> N <sub>5</sub> O <sub>8</sub>
<b>Molecular Weight:</b>	745.99
<b>Target:</b>	Microtubule/Tubulin; ADC Cytotoxin
<b>Pathway:</b>	Cell Cycle/DNA Damage; Cytoskeleton; Antibody-drug Conjugate/ADC Related
<b>Storage:</b>	Powder    -20°C    3 years 4°C        2 years



\* The compound is unstable in solutions, freshly prepared is recommended.

### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 200 mg/mL (268.10 mM; Need ultrasonic)					
	<b>Preparing Stock Solutions</b>	<b>Solvent</b>	<b>Mass</b>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
		<b>Concentration</b>				
		<b>1 mM</b>		1.3405 mL	6.7025 mL	13.4050 mL
		<b>5 mM</b>		0.2681 mL	1.3405 mL	2.6810 mL
	<b>10 mM</b>		0.1341 mL	0.6703 mL	1.3405 mL	
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 5 mg/mL (6.70 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: ≥ 5 mg/mL (6.70 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 5 mg/mL (6.70 mM); Clear solution</li> </ol>					

### BIOLOGICAL ACTIVITY

<b>Description</b>	Auristatin F is a potent cytotoxin in antitumor-conjugated agents and an analogue of MMAF. Auristatin F is a potent microtubule inhibitor and vascular damaging agent (VDA). Auristatin F inhibits cell division by preventing tubulin aggregation. Auristatin F can be used in antibody-drug conjugates (ADC) <sup>[1][2]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	Microtubule <sup>[1]</sup>
<b>In Vitro</b>	Auristatin F and Monomethyl Auristatin F (MMAF) are potent ADC cytotoxin used in antibody-drug conjugates <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**In Vivo**

Auristatin F (5 mg/kg; i.v.; male Sprague-Dawley rats) has  $C_{max}$  of 8276.76 ng/mL. The  $AUC_{last}$  is 65661.30 min\*ng/mL, and the clearance (CL) is 77.33 mL/min/kg, which is above the hepatic blood flow in the rat<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Sprague-Dawley rats<sup>[2]</sup>

Dosage: 5 mg/kg

Administration: Intravenous injection

**Result:**

Parameter	
Dose (i.v.) mg/kg	5
$C_{max}$ (ng/mL)	8276.76
$AUC_{last}$ (min*ng/mL)	62661.30
CL (mL/min/kg)	77.33
Vss (mL/Kg)	1057.13

**REFERENCES**

[1]. Park MH, et al. Pharmacokinetic and Metabolism Studies of Monomethyl Auristatin F via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry. *Molecules*. 2019 Jul 29;24(15):2754.

[2]. Roy S, et al. SMI-Ribosome inactivating protein conjugates selectively inhibit tumor cell growth. *Chem Commun (Camb)*. 2017 Apr 11;53(30):4234-4237.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA